DEXTENZA is an advancement in steroid treatment

  • Resorbable, so no need for removal1
    • Insert can be removed via saline irrigation or manual expression, if necessary1
  • Physicians rated DEXTENZA as easy to insert2,3*
  • Designed to deliver a tapered dose4
  • Contains fluorescein for visualization1
  • No additional components or assembly required1

*73.6% of physicians in Study 1, 76.4% in Study 2 and 79.6% in Study 3, for the treatment of ocular inflammation and pain following ophthalmic surgery, rated DEXTENZA as easy to insert.2,3

Consider the preservative load

Preservatives (e.g., benzalkonium chloride) in some topical drops can cause changes in the ocular surface, which may lead to inflammation and damage to the tear film.5



DEXTENZA is dexamethasone delivered via hydrogel technology1-3


  • With moisture and swells to fit securely in the canaliculus


  • Dexamethasone for up to 30 days


  • Slowly through the course of treatment and clears via the nasolacrimal duct

DEXTENZA is designed to:

  • Allow for physician-controlled administration4
  • Provide sustained coverage for up to 30 days1

Positive Patient Experience

Patients reported highly favorable outcomes in comfort, convenience, and satisfaction6

Survey results based on the responses from 201 DEXTENZA patients who participated in the most recent Phase 3 study for the treatment of ocular inflammation and pain following ophthalmic surgery6†

Study Limitations7

  • Qualitative written survey (questions not validated)
  • Relied on recall in an elderly population

Intent-to-treat population.

References: 1. DEXTENZA [package insert). Bedford. MA: Ocular Therapeutlx, Inc: 2021. 2. Walters T et al. J Clin Exp Ophthalmol. 2016;7(4): 1-11. 3. Tyson S. et al. J Cataract Refract Surg 2019; 45:204–212.[erratumin: 2019;45(6):895] 4. Sawhney AS,et al., inventors; Incept, LLC, assignee. Drug delivery through hydrogel plugs. US patent 8,409,606 B2. April 2, 2013. 5. Baudouin C et al. Prog Retin Eye Res. 2010;29(4):312-334. 6. Data on file 00837. Ocular Therapeutix, Inc. 7. Noecker RJ, et al. Evaluating the Physician and Patient Experience of a Dexamethasone Insert (0.4 mg) in Patients Having Cataract Surgery. Presented at: American Society of Cataract and Refractive Surgery Annual Meeting. April 16, 2018; Washington, DC.

full Prescribing Information

DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.

Intraocular Pressure Increase – Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Bacterial Infections – Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Viral Infections – Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal Infections – Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Delayed Healing – Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Other Potential Corticosteroid Complications – The initial prescription and renewal of medication order of DEXTENZA should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.

Ocular Inflammation and Pain Following Ophthalmic Surgery
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%), intraocular pressure increased (6%), visual acuity reduced (2%), cystoid macular edema (1%), corneal edema (1%), eye pain (1%), and conjunctival hyperemia (1%). The most common non-ocular adverse reaction was headache (1%).

Itching Associated with Allergic Conjunctivitis
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: intraocular pressure increased (3%), lacrimation increased (1%), eye discharge (1%), and visual acuity reduced (1%). The most common non-ocular adverse reaction was headache (1%).


DEXTENZA is a corticosteroid indicated for:

  • The treatment of ocular inflammation and pain following ophthalmic surgery.
  • The treatment of ocular itching associated with allergic conjunctivitis.